[Prognostic significance of early molecular response after second-line treatment with dasatinib of chronic myeloid leukemia patients]

Zhonghua Xue Ye Xue Za Zhi. 2019 Jul 14;40(7):608-611. doi: 10.3760/cma.j.issn.0253-2727.2019.07.015.
[Article in Chinese]
No abstract available

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Dasatinib / therapeutic use*
  • Humans
  • Leukemia, Myeloid, Chronic-Phase / drug therapy*
  • Prognosis
  • Protein Kinase Inhibitors
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Dasatinib